Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2018 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

WALTHAM, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
March 05, 2018 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and...
February 27, 2018 07:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Reports 2017 Financial Results and Company Update

2017 GAAP Revenue Increased 15% Year-over-Year February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass.,...
February 20, 2018 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET

WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday,...
February 14, 2018 18:03 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women

WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena® subcutaneous...
February 05, 2018 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)

WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden...
January 08, 2018 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance

WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including preliminary unaudited fourth quarter and full year 2017...
December 21, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Awards $300,000 in Grants to Further Research in Preterm Birth and Neonatal Health

WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- As part of the company’s ongoing support of maternal and neonatal health, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has awarded...
December 20, 2017 16:01 ET | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the 36th Annual...
December 20, 2017 08:00 ET | Source: AMAG Pharmaceuticals, Inc.

New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"

WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the issuance of U.S. Patent Number 9,844,558 entitled “Methods of Reducing Risk of Preterm...